Multicenter, single group study of aripiprazole efficacy and safety in the acute psychosis treatment of schizophrenia, schizophreniform disorder and schizoaffective disorder

Trial Profile

Multicenter, single group study of aripiprazole efficacy and safety in the acute psychosis treatment of schizophrenia, schizophreniform disorder and schizoaffective disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms APLUS
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Dec 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top